As a result of what we learnt from the mapping of the Human Genome, we were beginning to understand more clearly the role of genetics and the potential that genomic technologies could play in predicting disease. In addition, notwithstanding that Genomic medicine could offer real hope, there are many complex issues surrounding this revolution that needed to be addressed and discussed in an open and collaborative environment. The Journal of Precision Medicine aims to will do exactly this. JoPM covers a comprehensive continuum from discovery to diagnosis and discuss the confluence of genomic technologies and diagnostic tools that will play their part in detecting disease and offer insights into therapeutic solutions for a range of hitherto unmet medical needs. We encourage challenging debate surrounding payers, providers and regulators. We discuss the bio ethical and legal ramifications of Big Data and most importantly issues surrounding patient engagement. Looking beyond oncology, Biomarker R&D efforts now extend into new therapeutic areas such as immunology, infectious diseases and CNS disorders. The adoption and integration of companion diagnostics are paramount in the success of Precision Medicine - how to navigate the regulatory path to ensure commercial success is a constant challenge and one that needs to be faced head on. With a clearer picture of the many molecular pathways and the heterogeneity of many diseases such as cancer and diabetes, we are unquestionably at an inflection point in modern medicine. Despite some tremendous advancements in this field, progress is still too slow, so The Journal of Precision Medicine is committed to highlighting the obstacles we all face as participants of this endeavor, and through global engagement on all these issues we will ultimately drive the concept and reality of Precision Medicine forward.